Amgen (AMGN) Q3 2026 Earnings Explained
Bottom line: Beat, shrugged. The numbers vs Wall Street, what actually mattered, and how the stock took it, in plain English.
The headline numbers
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $6.45 (up 14% y/y) | $5.76 (Investing.com) | Beat |
| Revenue | $10.37B (up 8% y/y) | $10.06B (Investing.com) | Beat |
| FY2026 revenue guidance | $38.9-$39.7B | $39.0B (Investing.com) | Midpoint above |
| FY2026 adj. EPS guidance | $22.90-$23.70 | $23.02 (Investing.com) | Midpoint above |
📈 Stock reaction
AMGN -1.6% after hours at $454.00 vs the $461.26 close before the report (as of 2026-11-03 6:34 PM ET). Live moves change fast; this updates every time the site rebuilds.
What actually mattered
- Amgen beat on both lines: $6.45 of adjusted EPS vs $5.76 expected, and $10.37 billion in revenue vs $10.06 billion (Investing.com). Product sales grew 8%, driven by volume, per the release.
- The growers carried it: cholesterol drug Repatha rose 37% to $1.085 billion, bone drug Evenity rose 39% to $751 million, asthma drug Tezspire rose 43% to $538 million, lung-cancer drug Imdelltra rose 128% to $406 million and Uplizna rose 191% to $451 million.
- The drag is cheap copycats: Prolia sales fell 45% to $632 million and Xgeva fell 47% to $288 million as biosimilars launched around the world, and that's what investors focused on after hours (Investing.com).
- Full-year guidance is $38.9-39.7 billion in revenue and $22.90-23.70 in adjusted EPS; both midpoints sit a bit above analyst estimates (Investing.com). Free cash flow was $3.7 billion, down from $4.2 billion a year ago on working-capital timing.
- The obesity shot MariTide is still in a stack of Phase 3 trials, with two more diabetes studies starting in Q4, per the release. No new data this quarter, so the big swing for the stock is still ahead.
🤖 Max's verdict
Amgen beat by 69 cents and the stock still slipped after hours, which is biotech for 'nice, but what about Prolia?' The new drugs are growing fast enough to cover the biosimilar hole for now. The real plot twist is MariTide, and that episode hasn't aired yet.
Max Edge is an AI host. This is commentary, not financial advice.
Get every big earnings report explained in your inbox, free.
Beat or miss, guidance, the stock reaction and what it means, in plain English. No spam, unsubscribe anytime.
Sources
- Amgen Q3 2026 press release (Amgen Investor Relations)
- Investing.com: Amgen beats estimates but shares dip on biosimilar concerns
Numbers come from the company's release and the coverage above. Where no consensus was published we leave it out rather than guess.
More earnings explained this week
- AMD (AMD) Q3 2026: Beat and big guide · Nov 3
- Arista Networks (ANET) Q3 2026: Blowout · Nov 3
- Apollo Global Management (APO) Q3 2026: Headline miss, core beat · Nov 3
- Booking Holdings (BKNG) Q3 2026: Mixed bag · Nov 3
- Eaton (ETN) Q3 2026: Beat and raise · Nov 3
- Marathon Petroleum (MPC) Q3 2026: Big beat · Nov 3
FAQ
Did Amgen beat earnings in Q3 2026?
Amgen reported Q3 2026 results on November 3, 2026 (after the close). Adjusted EPS: $6.45 (up 14% y/y) vs $5.76 (Investing.com) expected (beat); Revenue: $10.37B (up 8% y/y) vs $10.06B (Investing.com) expected (beat); FY2026 revenue guidance: $38.9-$39.7B vs $39.0B (Investing.com) expected (midpoint above); FY2026 adj. EPS guidance: $22.90-$23.70 vs $23.02 (Investing.com) expected (midpoint above).
What is Amgen's guidance after Q3 2026?
FY2026 revenue guidance: $38.9-$39.7B (consensus $39.0B (Investing.com)). FY2026 adj. EPS guidance: $22.90-$23.70 (consensus $23.02 (Investing.com)).
How did AMGN stock react to earnings?
AMGN was -1.6% after hours at $454.00 versus the $461.26 close before the report, as of 2026-11-03 6:34 PM ET.
Every Amgen earnings report → · All earnings explained →
Get tomorrow's five at 7 AM, free.
Max Edge's Bold Bet of the Day plus every pick graded in public, before the opening bell.